---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-21-006115"
form_type: "8-K"
ticker: "BICX"
cik: "0001443863"
company_name: "BioCorRx Inc."
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T06:05:46.214832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant

## Summary
- Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.
- Funding supports first-in-human clinical trial of BICX104, an implantable naltrexone pellet for opioid use disorder.
- Company previously received FDA clearance to proceed to human trials; aims to begin trial in 2021.
- Grant is non-dilutive, covering substantial costs toward FDA approval for BICX104.

## SEC filing metadata
- accession: 0001477932-21-006115
- form_type: 8-K
- ticker: BICX
- cik: 0001443863
- company_name: BioCorRx Inc.
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1443863/000147793221006115/0001477932-21-006115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1443863/000147793221006115/bicx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-21-006115
- JSON: https://secwatch.observer/filing/0001477932-21-006115.json
- Plain text: https://secwatch.observer/filing/0001477932-21-006115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.